可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1]中华医学会心血管病学分会.中国慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095.
[2]Hogg K,Swedberg K,McMurray J.Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics,and prognosis[J].Am Coll Cardiol,2004,43(3):317-327.
[3]Owan TE,Hodge DO,Herges RM,et al.Trends in prevalence and outcome of heart failure with preserved ejection fraction[J].N Engl J Med,2006,355(3):251-259.
[4]Lee DS,Gona P,Vasan RS,et al.Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction:insights from the framingham heart study of the national heart,lung,and blood institute[J].Circulation,2009,119(24):3070-3077.
[5]Parissis JT,Ikonomidis I,Rafouli-Stergiou P,et al.Clinical characteristics and predictors of in-hospital mortality in acute heart failure with preserved left ventricular ejection fraction[J].Am J Cardiol,2011,107(1):79-84.
[6]Bursi F,Weston SA,Redfield MM,et al.Systolic and diastolic heart failure in the community[J].JAMA,2006,296(18):2209-2216.
[7]Olsson LG,Swedberg K,Ducharme A,et al.Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction:results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program[J].J Am Coll Cardiol,2006,47(10):1997-2004.
[8]Caldwell JC,Mamas MA.Heart failure, diastolic dysfunction and atrial fibrillation; mechanistic insight of a complex inter-relationship[J].Heart Fail Rev,2012,17(1):27-33.
[9]Heymans S,Hirsch E,Anker SD,et al.Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail, 2009, 11(2):119-129.
[10]Araújo JP, Louren?o P,Azevedo A,et al.Prognostic value of high-sensitivity C-reactive protein in heart failure:a systematic review[J].J Card Fail,2009,15(3):256-266.